HELX

Fund Description
The Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund s investment theme of genomic advancements. The Fund invests predominantly in common stock. The Fund s investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes.
Fund Profile
Fund Name Franklin Genomic Advancements ETF
Fund Exchange Ticker HELX
Fund Sponsor Franklin Templeton
Fund ISIN US35473P5200
Net Expense Ratio 0.50 %
Fund Inception Date 25 February 2020
Fund Legal Structure ETF (Open end fund)
Exchange BATS
Listing Country Code US
Fund Investment Objective
ETF Type Specific Global or ExUS Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Active
Index Name Not Applicable
Index Provider Not Applicable
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent Not Applicable
Key Statistics
Return As of Date 31 July 2020
Asset Under Management 3.42 Million (USD)
1 Month Total Return 9.31 %
Year To Date Return 42.58 %
1 Year Total Return
3 Year Annualized Total Return
NAV 34.18
Share Outstanding 100,000
Top 10 Holdings (30 July 2020)
Constituent Name Constituent Ticker Constituent Type Weighting
LIVONGO HEALTH INC LVGO EQUI 0.0502000000
WUXI BIOLOGICS CAYMAN INC 2269 EQUI 0.0484000000
LONZA GROUP AG-REG LONN EQUI 0.0445000000
REPLIGEN CORP RGEN EQUI 0.0440000000
ILLUMINA INC ILMN EQUI 0.0406000000
VEEVA SYSTEMS INC-CLASS A VEEV EQUI 0.0388000000
CRISPR THERAPEUTICS AG CRSP EQUI 0.0382000000
QUIDEL CORP QDEL EQUI 0.0380000000
CATALENT INC CTLT EQUI 0.0321000000
VERTEX PHARMACEUTICALS INC VRTX EQUI 0.0313000000